Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05348577




Registration number
NCT05348577
Ethics application status
Date submitted
18/03/2022
Date registered
27/04/2022
Date last updated
8/10/2024

Titles & IDs
Public title
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Scientific title
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Secondary ID [1] 0 0
2023-504996-26
Secondary ID [2] 0 0
D361EC00001
Universal Trial Number (UTN)
Trial acronym
CAPItello280
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - capivasertib
Treatment: Drugs - docetaxel
Other interventions - placebo
Treatment: Drugs - docetaxel

Experimental: capivasertib + docetaxel - Participants receive capivasertib in combination with docetaxel and steroids on a background of ADT.

Placebo comparator: placebo + docetaxel - Participants receive placebo in combination with docetaxel and steroids on a background of ADT.


Treatment: Drugs: capivasertib
320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.

Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.

Treatment: Drugs: docetaxel
Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.

Other interventions: placebo
matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.

Treatment: Drugs: docetaxel
Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS) in the overall population
Timepoint [1] 0 0
up to approximately 52 months
Secondary outcome [1] 0 0
Overall Survival (OS) in patients with mCRPC and PTEN-proficient tumours (IHC)
Timepoint [1] 0 0
up to approximately 52 months
Secondary outcome [2] 0 0
Overall Survival (OS) in patients with mCRPC and PTEN-deficient tumours (IHC).
Timepoint [2] 0 0
up to approximately 52 months
Secondary outcome [3] 0 0
Radiographic Progression-free Survival (rPFS) in the overall population
Timepoint [3] 0 0
up to approximately 40 months
Secondary outcome [4] 0 0
Time to pain progression (TTPP) in the overall population
Timepoint [4] 0 0
up to approximately 40 months
Secondary outcome [5] 0 0
Time to first Symptomatic Skeletal-Related Event (SSRE) in the overall population
Timepoint [5] 0 0
up to approximately 52 months
Secondary outcome [6] 0 0
Time to deterioration in urinary symptoms (TTDUS) in the overall population
Timepoint [6] 0 0
up to approximately 40 months
Secondary outcome [7] 0 0
Time to deterioration in Physical Functioning (TTDPF) in the overall population
Timepoint [7] 0 0
up to approximately 40 months
Secondary outcome [8] 0 0
Overall Pain Severity and Pain Interference as assessed by BPI-SF questionnaire in the overall population
Timepoint [8] 0 0
up to approximately 40 months
Secondary outcome [9] 0 0
Plasma concentration of capivasertib derived from a population PK model in the overall population
Timepoint [9] 0 0
pre dose (up to 90 minutes prior) and post dose (1 hour, 2 hours and 4 hours post dose)
Secondary outcome [10] 0 0
Radiographic Progression-free Survival (rPFS) in patients with mCRPC and PTEN-proficient tumours (IHC)
Timepoint [10] 0 0
up to approximately 40 months
Secondary outcome [11] 0 0
Radiographic Progression-free Survival (rPFS) in patients with mCRPC and PTEN-deficient tumours (IHC)
Timepoint [11] 0 0
up to approximately 40 months

Eligibility
Key inclusion criteria
* Histologically-confirmed prostate adenocarcinoma without predominant neuroendocrine or small cell cancers
* Metastatic disease documented prior to randomisation by clear evidence of = 1 bone lesion (defined as 1 lesion with positive uptake on bone scan) and/or = 1 soft tissue lesion (measurable or non-measurable)
* Patient must have been previously treated with a next generation hormonal agent (NHA), ie, abiraterone, enzalutamide, apalutamide or darolutamide, for prostate cancer for at least 3 months and shown evidence of disease progression (radiological or via PSA assessment) while receiving the NHA
* Evidence of mCRPC with progression of disease despite androgen deprivation therapy (ADT)
* Serum testosterone level = 50 ng/dL
* Candidate for docetaxel and steroid therapy
* Ongoing ADT with LHRH agonist, LHRH antagonist, or bilateral orchiectomy
* Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1 and anticipated minimum life expectancy of 12 weeks
* Confirmation that archival formalin-fixed paraffin-embedded (FFPE) tumour tissue sample which meets the minimum pathology and sample requirements is available to send to the central laboratory
* Able and willing to swallow and retain oral medication
* Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm
Minimum age
18 Years
Maximum age
130 Years
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Radiotherapy with a wide field of radiation within 4 weeks before start of study treatment
* Major surgery (excl. placement of vascular access, transurethral resection of prostate, bilateral orchiectomy, internal stents) within 4 weeks of start of study treatment
* Brain metastases,or spinal cord compression (unless spinal cord compression is asymptomatic and stable and not requiring steroids for at least 4 weeks prior to start of study treatment)
* Any of the following cardiac criteria:

i. Mean resting corrected QT interval (QTc) >470 msec from 3 consecutive ECGs ii. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG iii. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age,or any concomitant medication known to prolong the QT interval iv. Experience of any of the following procedures or conditions in the preceding 3 months: coronary artery bypass graft, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure NYHA Grade =2 v. Symptomatic hypotension - systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg vi. haemodinamic instability
* Clinically significant abnormalities of glucose metabolism as defined by any of the following:

i. Patients with diabetes mellitus (DM) type 1 or DM type 2 requiring insulin treatment ii. HbA1c =8.0% (63.9 mmol/mol)
* Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

i. Absolute neutrophil count < 1.5x 10^9/L ii. Platelet count < 100x 10^9/L iii. Haemoglobin < 9 g/dL (< 5.59 mmol/L) iv. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5x upper limit of normal (ULN) if no demonstrable liver metastases or > 5x ULN in the presence of liver metastases. Elevated alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastases and liver function is otherwise considered adequate in the investigator's judgement v. Total bilirubin > 1.5x ULN (participants with confirmed Gilbert's syndrome may be included in the study with a higher value) vi. Creatinine clearance < 50 mL/min per the Cockcroft and Gault formula without the need for chronic dialysis;
* As judged by the investigator, any evidence of diseases (including severe or uncontrolled systemic diseases, uncontrolled hypertension, history of interstitial pneumonia / pneumonitis or interstitial lung disease, renal transplant and active bleeding diseases), which, in the investigator's opinion, makes it undesirable for the patient to participate in the study or that would jeopardise compliance with the protocol.
* Refractory nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib
* Any other disease, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent. Evidence of dementia, altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent.
* Previous allogeneic bone marrow transplant or solid organ transplant
* History of another primary malignancy except for malignancy treated with curative intent with no known active disease =2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease.
* Persistent toxicities (CTCAE Grade =2) caused by previous anticancer therapy, excluding alopecia. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss)
* Known to have active hepatitis infection.
* Known to have human immunodeficiency virus (HIV) with a detectable viral RNA load or a CD4+ T-cell count < 350 cells/uL or a history of an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months, or receiving anti-HIV medications for less than 4 weeks.
* Known to have active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
* Treatment with any of the following:

i. Prior chemotherapy for CRPC. Chemotherapy for metastatic or localized HSPC (including docetaxel) is allowed provided that chemotherapy was completed = 6months before randomisation and progression of the prostate cancer occurred = 6months after the completion of therapy.

ii. Prior exposure to AKT inhibitors or PI3K inhibitors iii. Any investigational agents or study drugs from a previous clinical study within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment iv. Any other immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents (except ADT) within 3 weeks of the first dose of study treatment v. Strong inhibitors or strong inducers of cytochrome P450 (CYP)3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), vi.Use of any live vaccine administration 30 days prior to the initiation of study treatment, during, and for at least 90 days after the last dose of the study treatment

* Drugs known to significantly prolong the QT interval and associated with Torsade de Pointes within 5 half-lives of the first dose of study treatment
* History of hypersensitivity to active or inactive excipients of capivasertib, docetaxel, or drugs with a similar chemical structure or class
* Any restriction or contraindication based on the local prescribing information that would prohibit the use of docetaxel

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/03/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
21/12/2026
Actual
Sample size
Target
Accrual to date
Final
1017
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Birtinya
Recruitment hospital [2] 0 0
Research Site - Greenslopes
Recruitment hospital [3] 0 0
Research Site - Kogarah
Recruitment hospital [4] 0 0
Research Site - North Adelaide
Recruitment hospital [5] 0 0
Research Site - Orange
Recruitment hospital [6] 0 0
Research Site - Redcliffe
Recruitment hospital [7] 0 0
Research Site - Wahroonga
Recruitment postcode(s) [1] 0 0
4575 - Birtinya
Recruitment postcode(s) [2] 0 0
4120 - Greenslopes
Recruitment postcode(s) [3] 0 0
2217 - Kogarah
Recruitment postcode(s) [4] 0 0
5000 - North Adelaide
Recruitment postcode(s) [5] 0 0
2800 - Orange
Recruitment postcode(s) [6] 0 0
4020 - Redcliffe
Recruitment postcode(s) [7] 0 0
2076 - Wahroonga
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Maryland
Country [5] 0 0
United States of America
State/province [5] 0 0
Minnesota
Country [6] 0 0
United States of America
State/province [6] 0 0
New Jersey
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
South Dakota
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Virginia
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
Belgium
State/province [17] 0 0
Brasschaat
Country [18] 0 0
Belgium
State/province [18] 0 0
Gent
Country [19] 0 0
Belgium
State/province [19] 0 0
Liège
Country [20] 0 0
Brazil
State/province [20] 0 0
Cachoeiro de Itapemirim
Country [21] 0 0
Brazil
State/province [21] 0 0
Ijuí
Country [22] 0 0
Brazil
State/province [22] 0 0
Itajai
Country [23] 0 0
Brazil
State/province [23] 0 0
Joinville
Country [24] 0 0
Brazil
State/province [24] 0 0
Porto Alegre
Country [25] 0 0
Brazil
State/province [25] 0 0
Recife
Country [26] 0 0
Brazil
State/province [26] 0 0
Rio de Janeiro
Country [27] 0 0
Brazil
State/province [27] 0 0
Rio De Janeiro
Country [28] 0 0
Brazil
State/province [28] 0 0
Salvador
Country [29] 0 0
Brazil
State/province [29] 0 0
Santa Maria
Country [30] 0 0
Brazil
State/province [30] 0 0
Sao Paulo
Country [31] 0 0
Brazil
State/province [31] 0 0
São José Do Rio Preto - SP
Country [32] 0 0
Brazil
State/province [32] 0 0
São Paulo
Country [33] 0 0
Brazil
State/province [33] 0 0
Tres Lagoas
Country [34] 0 0
Canada
State/province [34] 0 0
Nova Scotia
Country [35] 0 0
Canada
State/province [35] 0 0
Ontario
Country [36] 0 0
Canada
State/province [36] 0 0
Quebec
Country [37] 0 0
Canada
State/province [37] 0 0
Toronto
Country [38] 0 0
Chile
State/province [38] 0 0
Santiago
Country [39] 0 0
Chile
State/province [39] 0 0
Vina del Mar
Country [40] 0 0
China
State/province [40] 0 0
Beijing
Country [41] 0 0
China
State/province [41] 0 0
Changsha
Country [42] 0 0
China
State/province [42] 0 0
Chengdu
Country [43] 0 0
China
State/province [43] 0 0
Chongqing
Country [44] 0 0
China
State/province [44] 0 0
Guangzhou
Country [45] 0 0
China
State/province [45] 0 0
Hangzhou
Country [46] 0 0
China
State/province [46] 0 0
Harbin
Country [47] 0 0
China
State/province [47] 0 0
Jiaxing
Country [48] 0 0
China
State/province [48] 0 0
Nanchang
Country [49] 0 0
China
State/province [49] 0 0
Nanjing
Country [50] 0 0
China
State/province [50] 0 0
Nantong
Country [51] 0 0
China
State/province [51] 0 0
Ningbo
Country [52] 0 0
China
State/province [52] 0 0
Shanghai
Country [53] 0 0
China
State/province [53] 0 0
Shenyang
Country [54] 0 0
China
State/province [54] 0 0
Tianjin
Country [55] 0 0
China
State/province [55] 0 0
Wuhan
Country [56] 0 0
China
State/province [56] 0 0
Yantai
Country [57] 0 0
China
State/province [57] 0 0
Zhengzhou
Country [58] 0 0
Czechia
State/province [58] 0 0
Horovice
Country [59] 0 0
Czechia
State/province [59] 0 0
Hradec Kralove
Country [60] 0 0
Czechia
State/province [60] 0 0
Pardubice
Country [61] 0 0
Czechia
State/province [61] 0 0
Praha 10
Country [62] 0 0
Czechia
State/province [62] 0 0
Praha 4
Country [63] 0 0
Czechia
State/province [63] 0 0
Praha 5
Country [64] 0 0
France
State/province [64] 0 0
Bordeaux
Country [65] 0 0
France
State/province [65] 0 0
Brest
Country [66] 0 0
France
State/province [66] 0 0
Clermont-Ferrand CEDEX 01
Country [67] 0 0
France
State/province [67] 0 0
Creteil
Country [68] 0 0
France
State/province [68] 0 0
Montpellier
Country [69] 0 0
France
State/province [69] 0 0
Paris
Country [70] 0 0
France
State/province [70] 0 0
Rouen
Country [71] 0 0
France
State/province [71] 0 0
Saint Herblain Cedex
Country [72] 0 0
France
State/province [72] 0 0
Saint-Mande
Country [73] 0 0
France
State/province [73] 0 0
Strasbourg
Country [74] 0 0
France
State/province [74] 0 0
Vandoeuvre Les Nancy
Country [75] 0 0
France
State/province [75] 0 0
Villejuif Cedex
Country [76] 0 0
Greece
State/province [76] 0 0
Athens
Country [77] 0 0
Greece
State/province [77] 0 0
Chaidari
Country [78] 0 0
Greece
State/province [78] 0 0
Marousi
Country [79] 0 0
Greece
State/province [79] 0 0
Patras
Country [80] 0 0
Greece
State/province [80] 0 0
Peiraias
Country [81] 0 0
Hungary
State/province [81] 0 0
Budapest
Country [82] 0 0
Hungary
State/province [82] 0 0
Kecskemét
Country [83] 0 0
Hungary
State/province [83] 0 0
Nyiregyhaza
Country [84] 0 0
Hungary
State/province [84] 0 0
Szeged
Country [85] 0 0
Hungary
State/province [85] 0 0
Szolnok
Country [86] 0 0
India
State/province [86] 0 0
Bikaner
Country [87] 0 0
India
State/province [87] 0 0
Meerut
Country [88] 0 0
India
State/province [88] 0 0
Mohali
Country [89] 0 0
India
State/province [89] 0 0
New Delhi
Country [90] 0 0
Israel
State/province [90] 0 0
Be'er Ya'akov
Country [91] 0 0
Israel
State/province [91] 0 0
Haifa
Country [92] 0 0
Israel
State/province [92] 0 0
Jerusalem
Country [93] 0 0
Israel
State/province [93] 0 0
Kfar Sava
Country [94] 0 0
Israel
State/province [94] 0 0
Petah Tikva
Country [95] 0 0
Israel
State/province [95] 0 0
Ramat Gan
Country [96] 0 0
Israel
State/province [96] 0 0
Tel Aviv
Country [97] 0 0
Japan
State/province [97] 0 0
Chiba-shi
Country [98] 0 0
Japan
State/province [98] 0 0
Hirakata-shi
Country [99] 0 0
Japan
State/province [99] 0 0
Hirosaki-shi
Country [100] 0 0
Japan
State/province [100] 0 0
Kanazawa-shi
Country [101] 0 0
Japan
State/province [101] 0 0
Kashihara-shi
Country [102] 0 0
Japan
State/province [102] 0 0
Kita-gun
Country [103] 0 0
Japan
State/province [103] 0 0
Kobe-shi
Country [104] 0 0
Japan
State/province [104] 0 0
Kumamoto-shi
Country [105] 0 0
Japan
State/province [105] 0 0
Miyazaki-shi
Country [106] 0 0
Japan
State/province [106] 0 0
Nagano-Shi
Country [107] 0 0
Japan
State/province [107] 0 0
Nagoya-shi
Country [108] 0 0
Japan
State/province [108] 0 0
Nakano-Ku
Country [109] 0 0
Japan
State/province [109] 0 0
Osaka-shi
Country [110] 0 0
Japan
State/province [110] 0 0
Osakasayama-shi
Country [111] 0 0
Japan
State/province [111] 0 0
Sagamihara-shi
Country [112] 0 0
Japan
State/province [112] 0 0
Sapporo-shi
Country [113] 0 0
Japan
State/province [113] 0 0
Tsu-shi
Country [114] 0 0
Japan
State/province [114] 0 0
Wakayama-shi
Country [115] 0 0
Japan
State/province [115] 0 0
Yokohama-shi
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Bukgu
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Busan
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Goyang-si
Country [119] 0 0
Korea, Republic of
State/province [119] 0 0
Seoul
Country [120] 0 0
Mexico
State/province [120] 0 0
Aguascalientes
Country [121] 0 0
Mexico
State/province [121] 0 0
Ciudad de México
Country [122] 0 0
Mexico
State/province [122] 0 0
Culiacan
Country [123] 0 0
Mexico
State/province [123] 0 0
Guadalajara
Country [124] 0 0
Mexico
State/province [124] 0 0
Mexico
Country [125] 0 0
Mexico
State/province [125] 0 0
Oaxaca
Country [126] 0 0
Mexico
State/province [126] 0 0
Zapopan
Country [127] 0 0
Netherlands
State/province [127] 0 0
Den Haag
Country [128] 0 0
Netherlands
State/province [128] 0 0
Hoofddorp
Country [129] 0 0
Poland
State/province [129] 0 0
Nowa Sol
Country [130] 0 0
Poland
State/province [130] 0 0
Opole
Country [131] 0 0
Poland
State/province [131] 0 0
Wieliszew
Country [132] 0 0
Spain
State/province [132] 0 0
Barcelona
Country [133] 0 0
Spain
State/province [133] 0 0
Cordoba
Country [134] 0 0
Spain
State/province [134] 0 0
Lugo
Country [135] 0 0
Spain
State/province [135] 0 0
Madrid
Country [136] 0 0
Spain
State/province [136] 0 0
Malaga
Country [137] 0 0
Spain
State/province [137] 0 0
Sabadell
Country [138] 0 0
Spain
State/province [138] 0 0
Sevilla
Country [139] 0 0
Taiwan
State/province [139] 0 0
Kaohsiung
Country [140] 0 0
Taiwan
State/province [140] 0 0
Taichung
Country [141] 0 0
Taiwan
State/province [141] 0 0
Tainan
Country [142] 0 0
Taiwan
State/province [142] 0 0
Taipei
Country [143] 0 0
Turkey
State/province [143] 0 0
Adana
Country [144] 0 0
Turkey
State/province [144] 0 0
Edirne
Country [145] 0 0
Turkey
State/province [145] 0 0
Izmir
Country [146] 0 0
Turkey
State/province [146] 0 0
Sahinbey
Country [147] 0 0
Turkey
State/province [147] 0 0
Yüregir
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Edinburgh
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Glasgow
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Guildford
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Hackensack
Country [152] 0 0
United Kingdom
State/province [152] 0 0
London
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Manchester
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Southampton
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall survival is defined as the time from randomization until the date of death due to any cause.
Trial website
https://clinicaltrials.gov/study/NCT05348577
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05348577